Down 35% in a month, why there's good news for the Creso Pharma (ASX:CPH) share price today

Cannabis derived CBD is being used to treat a growing list of ailments.

| More on:
two men in formal business clothing closely inspect a bud from a cannabis crop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Creso Pharma share price is higher today
  • The company's first CBD products are to be trial-marketed in the US via its acquisition target
  • Creso has flagged the potential to accelerate new product launches

The Creso Pharma Ltd (ASX: CPH) share price is up 2% in afternoon trade.

The company closed yesterday's trading at 51 cents and its shares are currently fetching 52 cents, after hitting an intraday high of 55 cents this morning.

Those gains will be welcomed by Creso Pharma shareholders who've watch the ASX medicinal cannabis share tumble 35% over the past month.

So, what's the good news for the Creso Pharma share price today?

Cross-selling opportunities progress

Today, Creso Pharma announced further progress for cross-selling opportunities with its acquisition target, Sierra Sage Herbs LLC.

Creso initially reported its acquisition intentions for the United States-based consumer packaged goods company on 3 February. Sierra Sage Herbs' portfolio includes a range of CBD (cannabidiol) products.

The Creso Pharma share price closed up 5.9% on the day of the announcement.

In today's release, the company reported it's about to send 35,000 of its CannaQIX 50 lozenge products from its Switzerland-based facility to Sierra Sage Herbs in the US. Those will then be marketed through SSH's leading Good Goo brand.

Creso said that the potential cross-selling opportunities could increase its sales in the US and accelerate new product launches.

Commenting on the progress, Creso Pharma's CEO William Lay said:

The initial shipment of Creso Pharma Switzerland products marks an important milestone and will allow us to test the market, as well as learn how consumers will engage with the Company's product suite. This will build an important foundation for us as we progress towards larger product launches upon closing of the transaction.

We are also very pleased with the completion of an initial ImpACTIVE product line through the group's contract manufacturer. By leveraging SSH's manufacturing relationships, as well as marketing, branding, e-commerce and big box retailer expertise and networks, we expect to significantly accelerate impACTIVE's route to market.

The Creso Pharma share price may also be getting a lift from the company's reiteration that it expects "another revenue stream for the company" from the launch of these products in the coming months.

Creso Pharma share price snapshot

If the past month has been difficult for the Creso Pharma share price, the past 12 months have been downright demanding.

Creso Pharma shares have tumbled 72% since this time last year. For some context, the All Ordinaries Index (ASX: XAO) has gained 5% over that same time.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »